Fedratinib is a potent tyrosine kinase inhibitor primarily indicated for the treatment of myeloproliferative neoplasms, such as primary and secondary myelofibrosis, by targeting and inhibiting JAK2, JAK1,… Read more






Fedratinib is a potent tyrosine kinase inhibitor primarily indicated for the treatment of myeloproliferative neoplasms, such as primary and secondary myelofibrosis, by targeting and inhibiting JAK2, JAK1, and FLT3 kinases. This collection provides essential tools for rigorous pharmaceutical analysis, including high-purity reference standards, process-related impurities, potential degradants like N-oxide or N-nitroso forms, and specific metabolites. These compounds are critical for laboratory professionals conducting impurity profiling and method validation, ensuring compliance with strict regulatory standards. Furthermore, stable isotope-labelled Fedratinib derivatives serve as internal standards in mass spectrometry-based bioanalytical assays, allowing for accurate quantification in complex matrices. By utilizing these specialized reference materials, laboratories can effectively monitor drug quality, perform stability testing, and maintain the precision required throughout the drug development and quality control lifecycle.